相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

n - 3多不和脂肪酸介导氧胆酸-FXR信号传递,以改善与代谢功能障碍相关的脂肪肝疾病

Yuan Wang¹, Yan-Fang Chen¹, Yi-Xuan Cong¹

¹Institute of Nutrition & Health, Qingdao University, Qingdao, China; School of Public Health, Qingdao University, Qingdao, China.

The Journal of nutritional biochemistry

|October 4, 2025

概括

欧米茄-3脂肪酸 (PUFA) 通过提高氧胆酸 (HDCA) 水平来改善与代谢功能障碍相关的脂肪肝疾病 (MAFLD). HDCA作为一个FXR对抗剂,减少胺和缓解MAFLD症状.

科学领域:

肝病学和胃肠道学
营养科学营养科学
代谢障碍代谢障碍代谢障碍

背景情况:

与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 是一个日益严重的健康问题.
欧米茄-3多不和脂肪酸 (PUFA) 缓解MAFLD的机制尚未完全理解.
肠道微生物群修饰的代谢物,包括胆酸,都与MAFLD的发病有关.

研究的目的:

阐明 n-3 PUFA 改善 MAFLD 的机制.
调查肠道微生物群修改的胆酸,特别是氧胆酸 (HDCA) 在MAFLD中的作用.
为了确定n-3PUFA,HDCA和MAFLD之间的因果关系.

主要方法:

在MAFLD患者和对照组中分析血清胆汁酸和红细胞脂脂肪酸的病例控制研究.
在MAFLD患者中对n-3PUFA补充剂进行双盲,随机,安慰剂对照试验.
用n-3PUFA,HDCA或C16:0-胺治疗的MAFLD小鼠模型.

主要成果:

MAFLD患者的血清HDCA水平较低,与n-3PUFA比例负相关.
在MAFLD患者中,PUFA补充剂显著增加了血清HDCA度.
n-3PUFA的使用可提高肝脏CYP7B1的调节,通过另一种胆酸途径增加HDCA的合成.
给小鼠的HDCA剂量通过对抗FXR减少了肝脏和肠道胺,改善了MAFLD.
陶胺的使用逆转了HDCA的有益作用.

结论:

n-3 PUFA通过另一种胆酸途径促进HDCA合成.
通过调节FXR-胺轴,HDCA可以改善MAFLD.
这项研究揭示了n-3PUFA在MAFLD治疗中的新机制.

关键词:

陶胺是一种陶胺.法尔内索伊德的X受体氧胆酸是什么? 氧胆酸是什么?与代谢功能障碍相关的脂肪肝疾病.n - 3多不和脂肪酸的使用情况

更多相关视频

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

相关概念视频

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Overview of Fatty Acid Metabolism

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):